Table 2.
Inflammatory mediators in patients with or without systemic treatment at baseline.
| Mediator, mean ± SD | No systemic treatment | Systemic treatment | P-value |
|---|---|---|---|
| n (eyes/patients) | 20/20 | 40/40 | |
| TNF-α (pg/mL) | 8.83 ± 6.17 | 9.39 ± 10.44 | 0.551 |
| IL-1β (pg/mL) | 0.91 ± 1.69 | 0.46 ± 0.52 | 0.432 |
| IL-6 (pg/mL) | 3.10 ± 5.86 | 6.44 ± 16.43 | 0.545 |
| IL-8 (pg/mL) | 13.66 ± 21.02 | 12.70 ± 11.57 | 0.960 |
| IL-10 (pg/mL) | 2.01 ± 6.52 | 0.52 ± 0.97 | 0.276 |
| IL-17 (pg/mL) | 10.7 ± 19.91 | 15.48 ± 30.68 | 0.778 |
| MCP-1 (pg/mL) | 617.41 ± 404.47 | 676.45 ± 409.43 | 0.846 |
| VEGF (pg/mL) | 275.58 ± 216.92 | 226.82 ± 155.29 | 0.389 |
| Tregs (% CD3+ CD4+ PoxP3+) | 3.78 ± 2.46 | 4.53 ± 2.76 | 0.392 |
TNF, tumor necrosis factor; IL, interleukin; MCP, monocyte chemoattractant protein; VEGF, vascular endothelial growth factor; Tregs, regulatory T lymphocytes.